<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18475">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02114710</url>
  </required_header>
  <id_info>
    <org_study_id>2009NLY078</org_study_id>
    <nct_id>NCT02114710</nct_id>
  </id_info>
  <brief_title>Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock</brief_title>
  <official_title>Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether stress doses of hydrocortisone attenuate
      coagulation dysfunction in patients with septic shock. And discuss the probable mechanism by
      which little doses of hydrocortisone influence coagulation system in sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to receive either low-dose hydrocortisone or matching
      placebo.Severity of coagulopathy was estimated using ISTH DIC score. We determined the
      complications and mortality in two groups, and analyzed the relationship between
      hydrocortisone and coagulopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>30 days after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical perioperative complications</measure>
    <time_frame>30 days after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical complications</measure>
    <time_frame>30 days after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MODS SOFA score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Coagulation Dysfunction in Septic Shock</condition>
  <condition>Hemodynamic Improvement Induced by Hydrocortisone</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>little doses of hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients(ageâ‰§18y)

          -  Admitted for septic shock were considered eligible if they had no life-threatening
             systemic disease (ASA groups 1~3)

        Exclusion Criteria:

          -  Lactation

          -  Mental disorders

          -  Disseminated cancer

          -  Secondary cancers

          -  Inflammatory bowel disease, or diseases hindering epidural analgesia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Gao Tao</investigator_full_name>
    <investigator_title>Nanjing PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>coagulopathy</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>organ failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
